$124.40
5.27% yesterday
Nasdaq, May 12, 10:02 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$124.40
+5.14 4.31% 1M
-43.88 26.08% 6M
-28.52 18.65% YTD
-100.94 44.79% 1Y
-69.92 35.98% 3Y
-195.37 61.10% 5Y
-239.71 65.83% 10Y
Nasdaq, Closing price Mon, May 12 2025
+6.23 5.27%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $18.23b
Enterprise Value $22.25b
P/E (TTM) P/E ratio 12.29
EV/FCF (TTM) EV/FCF 9.13
EV/Sales (TTM) EV/Sales 2.37
P/S ratio (TTM) P/S ratio 1.94
P/B ratio (TTM) P/B ratio 1.07
Revenue growth (TTM) Revenue growth 1.25%
Revenue (TTM) Revenue $9.40b
EBIT (operating result TTM) EBIT $2.13b
Free Cash Flow (TTM) Free Cash Flow $2.44b
Cash position $2.60b
EPS (TTM) EPS $10.13
P/E forward 11.51
P/S forward 1.97
EV/Sales forward 2.40
Short interest 2.81%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a Biogen forecast:

16x Buy
43%
21x Hold
57%

Analyst Opinions

37 Analysts have issued a Biogen forecast:

Buy
43%
Hold
57%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9,402 9,402
1% 1%
100%
- Direct Costs 3,146 3,146
7% 7%
33%
6,256 6,256
1% 1%
67%
- Selling and Administrative Expenses 1,646 1,646
18% 18%
18%
- Research and Development Expense 1,734 1,734
17% 17%
18%
2,876 2,876
27% 27%
31%
- Depreciation and Amortization 749 749
41% 41%
8%
EBIT (Operating Income) EBIT 2,127 2,127
23% 23%
23%
Net Profit 1,479 1,479
27% 27%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
Seeking Alpha
about 11 hours ago
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have ri...
Neutral
GlobeNewsWire
about 22 hours ago
Paris,  May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal.
Neutral
Seeking Alpha
11 days ago
Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priya Singhal - Head, Development Robin Kramer - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman...
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today